Scott W. Morrison - 15 Sep 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
15 Sep 2023
Net transactions value
$0
Form type
4
Filing time
19 Sep 2023, 16:25:56 UTC
Previous filing
30 Jun 2023
Next filing
08 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +1,333 1,333 15 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -1,333 -33% $0.000000 2,667 15 Sep 2023 Common Stock 1,333 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney